$87.80
13.89% yesterday
NYSE, Oct 30, 09:11 pm CET

Glaukos Corp Stock price

$87.80
+6.25 7.66% 1M
-6.45 6.84% 6M
-62.14 41.44% YTD
-50.88 36.69% 1Y
+31.73 56.59% 3Y
+31.88 57.01% 5Y
+67.76 338.12% 10Y
+56.58 181.23% 20Y
NYSE, Closing price Thu, Oct 30 2025
+10.71 13.89%

Key metrics

Basic
Market capitalization
$4.4b
Enterprise Value
$4.2b
Net debt
positive
Cash
$274.8m
Shares outstanding
57.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.2 | 8.9
EV/Sales
9.7 | 8.5
EV/FCF
negative
P/B
5.8
Financial Health
Equity Ratio
78.7%
Return on Equity
-19.1%
ROCE
-10.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$433.0m | $494.3m
EBITDA
$-55.8m | $-40.6m
EBIT
$-96.7m | $-59.2m
Net Income
$-92.8m | $-52.2m
Free Cash Flow
$-43.5m
Growth (TTM | estimate)
Revenue
26.7% | 28.9%
EBITDA
34.1% | 60.7%
EBIT
19.0% | 45.2%
Net Income
41.5% | 64.3%
Free Cash Flow
46.8%
Margin (TTM | estimate)
Gross
76.3%
EBITDA
-12.9% | -8.2%
EBIT
-22.3%
Net
-21.4% | -10.6%
Free Cash Flow
-10.1%
More
EPS
$-1.6
FCF per Share
$-0.8
Short interest
5.8%
Employees
995
Rev per Employee
$390.0k
Show more

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Glaukos Corp forecast:

18x Buy
82%
3x Hold
14%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Glaukos Corp forecast:

Buy
82%
Hold
14%
Sell
5%

Financial data from Glaukos Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
433 433
27% 27%
100%
- Direct Costs 102 102
28% 28%
24%
331 331
26% 26%
76%
- Selling and Administrative Expenses 287 287
17% 17%
66%
- Research and Development Expense 140 140
3% 3%
32%
-56 -56
34% 34%
-13%
- Depreciation and Amortization 41 41
17% 17%
9%
EBIT (Operating Income) EBIT -97 -97
19% 19%
-22%
Net Profit -93 -93
41% 41%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Positive
The Motley Fool
about 6 hours ago
The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.
Neutral
Seeking Alpha
one day ago
Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Divisi...
Neutral
Business Wire
one day ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% ...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Thomas Burns
Employees 995
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today